INTRODUCTION: The efficacy of platinum-based adjuvant chemotherapy (PBAC) for pathological stage II and stage III squamous cell carcinoma (SCC) of the lung was analyzed retrospectively. MATERIALS AND METHODS: The prognoses of 94 patients with stage II and stage III SCC with or without PBAC (more than three courses of cisplatin-, carboplatin-, and nedaplatin-based adjuvant chemotherapy) were compared. RESULTS: The mean observation period was 46.1 months. PBAC was not administered for the following reasons: 39 (55.7%) patients had comorbidities, 25 (35.7%) were older than 75 years, 19 (27.1%) patients underwent surgery before the approval of PBAC, and 3 (4.3%) patients could not continue PBAC (≤2 cycles) because of adverse events. PBAC patients (n = 24) were significantly younger than non-PBAC patients (n = 70; 66.3 vs 69.6 years old, respectively; p = 0.043). Disease-free survival (DFS) did not differ between PBAC and non-PBAC patients (55.0% and 67.1%, respectively; p = 0.266). PBAC patients tended to have worse overall survival (OS) than non-PBAC patients (56.1% and 70.2%, respectively; p = 0.138). PBAC was not prognostic for OS (hazard ratio (HR), 2.11; 95% confidence interval (CI), 0.82%-5.40%; p = 0.120). CONCLUSION: PBAC did not improve the prognoses of patients with pathological stage II or stage III SCC in the single institution experience.
INTRODUCTION: The efficacy of platinum-based adjuvant chemotherapy (PBAC) for pathological stage II and stage III squamous cell carcinoma (SCC) of the lung was analyzed retrospectively. MATERIALS AND METHODS: The prognoses of 94 patients with stage II and stage III SCC with or without PBAC (more than three courses of cisplatin-, carboplatin-, and nedaplatin-based adjuvant chemotherapy) were compared. RESULTS: The mean observation period was 46.1 months. PBAC was not administered for the following reasons: 39 (55.7%) patients had comorbidities, 25 (35.7%) were older than 75 years, 19 (27.1%) patients underwent surgery before the approval of PBAC, and 3 (4.3%) patients could not continue PBAC (≤2 cycles) because of adverse events. PBAC patients (n = 24) were significantly younger than non-PBAC patients (n = 70; 66.3 vs 69.6 years old, respectively; p = 0.043). Disease-free survival (DFS) did not differ between PBAC and non-PBAC patients (55.0% and 67.1%, respectively; p = 0.266). PBAC patients tended to have worse overall survival (OS) than non-PBAC patients (56.1% and 70.2%, respectively; p = 0.138). PBAC was not prognostic for OS (hazard ratio (HR), 2.11; 95% confidence interval (CI), 0.82%-5.40%; p = 0.120). CONCLUSION: PBAC did not improve the prognoses of patients with pathological stage II or stage III SCC in the single institution experience.
Authors: Sophie D Fosså; Ethel Gilbert; Graça M Dores; Jinbo Chen; Katherine A McGlynn; Sara Schonfeld; Hans Storm; Per Hall; Eric Holowaty; Aage Andersen; Heikki Joensuu; Michael Andersson; Magnus Kaijser; Mary Gospodarowicz; Randi Cohen; Eero Pukkala; Lois B Travis Journal: J Natl Cancer Inst Date: 2007-04-04 Impact factor: 13.506
Authors: Charles A Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David Gandara; David H Johnson; Kenneth A Kesler; Mark Green; Mark Vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: D Waller; M D Peake; R J Stephens; N H Gower; R Milroy; M K B Parmar; R M Rudd; S G Spiro Journal: Eur J Cardiothorac Surg Date: 2004-07 Impact factor: 4.191
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: E Josue Ruiz; Adan Pinto-Fernandez; Andrew P Turnbull; Linxiang Lan; Thomas M Charlton; Hannah C Scott; Andreas Damianou; George Vere; Eva M Riising; Clive Da Costa; Wojciech W Krajewski; David Guerin; Jeffrey D Kearns; Stephanos Ioannidis; Marie Katz; Crystal McKinnon; Jonathan O'Connell; Natalia Moncaut; Ian Rosewell; Emma Nye; Neil Jones; Claire Heride; Malte Gersch; Min Wu; Christopher J Dinsmore; Tim R Hammonds; Sunkyu Kim; David Komander; Sylvie Urbe; Michael J Clague; Benedikt M Kessler; Axel Behrens Journal: Elife Date: 2021-10-12 Impact factor: 8.140
Authors: E Josue Ruiz; Markus E Diefenbacher; Jessica K Nelson; Rocio Sancho; Fabio Pucci; Atanu Chakraborty; Paula Moreno; Alessandro Annibaldi; Gianmaria Liccardi; Vesela Encheva; Richard Mitter; Mathias Rosenfeldt; Ambrosius P Snijders; Pascal Meier; Marco A Calzado; Axel Behrens Journal: J Exp Med Date: 2019-01-14 Impact factor: 14.307